Fig. 3.

Risk for cardiovascular and kidney outcomes in SGLT2i initiators compared to oGLAs in low kidney risk populations, during the ITT follow up definition. A Cardiovascular outcomes. B Kidney outcomes. Event rates are presented as number of events per 100 person-years of follow up. Low KDIGO risk is defined as eGFR  >  60 ml/min/1.73 m² and UACR  <  30 mg/g. For the low KDIGO risk and eGFR  >  90 ml/min/1.73 m², the model was adjusted to baseline eGFR (as continuous variable) and UACR (as categorical variable). Outcome analysis of the urine albumin BDL category was only adjusted to baseline eGFR as continuous variable. *BDL  =  Below detectable levels. SGLT2i sodium/glucose cotransporter-2 inhibitors; oGLAs other glucose lowering agents; ITT intention to treat; hHF hospitalization for heart failure; ACM all-cause mortality; MI myocardial infract; eGFR estimated glomerular filtration rate; UACR urinary albumin to creatinine ratio; KDIGO kidney disease: improving global outcomes; ER event rate